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Background: Serum β-cryptoxanthin levels are lower in overweight subjects than in normal subjects. Abnormalities
of adipocytokine profiles in obesity subjects have been reported. There are several reports that serum
β-cryptoxanthin levels in them were relatively lower than normal subjects.
Objective: We hypothesize that supplementation of highly concentrated β-cryptoxanthin improves serum
adipocytokine profiles in obese subjects. This study tested the association between β-cryptoxanthin intake and
serum adipocytokine levels.
Methods: An intervention study consisted of a 3-week long before-and-after controlled trial, where β-cryptoxanthin
(4.7 mg/day) was given to 17 moderately obese postmenopausal women.
Results: The results indicated no significant changes in body weight or body mass index (BMI). Serum
β-cryptoxanthin levels increased significantly by 4-fold. Serum high molecular weight (HMW)-adiponectin levels
increased significantly, while serum plasminogen activator inhibitor (PAI)-1 levels decreased.
Conclusions: We concluded that increasing the intake of β-cryptoxanthin to approximately 4 mg per day for
3 weeks may have beneficial effects on the serum adipocytokine status and consequently alleviate progression of
metabolic syndrome.
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Serum β-cryptoxanthin levels (Figure 1) are lower in over-
weight subjects than in normal subjects, irrespective of
dietary intake [1]. In a case-controlled study, which was
part of a larger survey of 2895 subjects with body mass in-
dexes (BMI) greater than 25, serum β-cryptoxanthin levels
were found to be lower than in subjects with BMIs lower
than 25 [2]. Adipose tissue store excess energy in the form
of fat and secretes physiologically active substances known
as adipocytokines [3]. Among these compounds, adipo-
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reproduction in any medium, provided the orPlasma adiponectin levels are negatively correlated with
BMI in men and women [4]. Growing evidence suggests
that high-molecular weight (HMW)-adiponectin is the
most physiologically active form present in metabolic dis-
orders [5]. Plasminogen activator inhibitor-1 (PAI-1) is a
non-specific adipocytokine and its levels are positively cor-
related with the area of visceral fat determined by com-
puted tomography (CT) scan of obese and non-obese
subjects [6].
Serum β-cryptoxanthin levels have been reported in
subjects with metabolic syndrome [1], but no interven-
tion studies have provided dietary β-cryptoxanthin to
subjects. We hypothesize that supplementation of highly
concentrated β-cryptoxanthin improves serum adipocy-
tokine profiles in obese subjects. This study aimed toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and







Figure 1 The chemical structure of β-cryptoxanthin.
Table 1 Comparison of clinical data and daily intake of
nutrients before and after 3-weeks intake of a
β-cryptoxanthin beverage (n = 17)
Characteristics Before After Change1) P-value
Age (years) 55 ± 1.7 55 ± 1.7
Height (cm) 154.5 ± 0.9 154.5 ± 0.9
Body weight (kg) 64.9 ± 1.7 64.8 ± 1.7 −0.1 0.473
BMI (kg/cm2) 27.1 ± 0.6 27.1 ± 0.6 0 0.722
Blood pressure
SBP (mmHg) 134 ± 4.6 128 ± 3.7 −6 0.052
DBP (mmHg) 80 ± 2.2 79 ± 2.1 −1 0.366
Dietary intake per day2)
Energy (kcal) 1659 ± 101 1676 ± 96 17 0.805
Protein (g) 69.3 ± 3.7 67.5 ± 3.5 −1.8 0.597
Fat (g) 51.4 ± 3.8 50.9 ± 3.6 −0.4 0.943
Carbohydrate (g) 225.2 ± 15.4 223.9 ± 15.6 −1.4 0.916
Dietary fibre (g) 16.5 ± 1.0 20.1 ± 1.6 3.6 0.035
β-Cryptoxanthin (mg) 723 ± 237 4719 ± 6 3996 0.000
Vitamin C (mg) 133 ± 15 231 ± 7 98 0.000
Data show means ± S.E.
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure.
1) Change implies subtraction of ‘before’ data from ‘after’ data.
2) Included beverage.
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BMI of 25–30, who had been administered a beverage




Seventeen postmenopausal obese women participated in
this study. Obesity was defined as a body mass index
(BMI) greater than 25 kg/m2, according to the Japan So-
ciety for the Study of Obesity. Criteria for participation
in this study included no past history of diabetes melli-
tus, no use of prescribed medicine, and no history of
smoking. This study was approved by the Nakamura
Gakuen University Committee (No. 05–009), in accord-
ance with the Declaration of Helsinki. Written informed
consent was obtained from all participants.
The daily nutrient intake of the subjects was moni-
tored for 3 days before the start and 3 days after the
study by means of dietary records. Subjects were
instructed to continue with their usual diets, but were
prohibited from the intake of citrus fruits, persimmon,
and the juices of either fruits during the period of the in-
vestigation. The nutrient intake was calculated using
Excel Eiyou-kun ver. 3 (Kenpaku-sha, Tokyo, Japan).
The intervention study was a 3-week long before-and-
after controlled trial, where 200 ml of a beverage con-
taining β-cryptoxanthin (1.56 mg/serving and 4.7 mg/
day) was provided to the subjects. Other ingredients of
the beverage which we determined were as follows, en-
ergy (27 kcal/serving), water (183.4 g/serving), protein
(0.6 g/serving), lipids (< 0.2 g/serving), ash (< 0.2 g/
serving), total carbohydrate (6.1 g/serving), sugars
(3.78 g/serving), dietary fiber (1.1 g/serving), potassium
(71.6 mg/serving), calcium (12.0 mg/serving), sodium
(0.8 mg/serving), magnesium (5.7 mg/serving), vitamin
C (49.10 mg/serving), β-carotene (0.19 mg/serving).
The beverage was prepared from residues generated by
the process used in the manufacture of satsuma man-
darin juice. The residues contained higher concentra-
tions of β-cryptoxanthin than the manufactured juice.
The beverage was prepared by resuspending the resi-
dues in water, and β-cryptoxanthin levels in the bever-
age were identical in each serving.Blood sampling and biochemical measurements
Blood samples were assayed for total cholesterol, trigly-
ceride, high-density lipoprotein (HDL) cholesterol, glu-
cose, HMW-adiponectin, leptin, total PAI-1, and insulin
in a commercial laboratory (SRL, Fukuoka, Japan).
Plasma carotenoid levels were measured in a commercial
laboratory (BIKEN, Kyoto, Japan). Plasma carotenoids,
including, α -carotene, β-carotene, β-cryptoxanthin,
lycopene, and lutein-zeaxanthin, were extracted and
concentrated using standard methods. These com-
pounds were then quantified by reversed-phase high-
performance liquid chromatography (HPLC).
Statistical analyses
All values are expressed as mean ± SE. The statistical dif-
ference was determined using a two-tailed paired t-test.
P < 0.05 was considered significant.
Results
The baseline characteristics of the subjects at the begin-
ning of the investigation are shown in Table 1. Postme-
nopausal women were selected on the basis of BMI. The
highest BMI was 32.1 and the lowest was 23.1. There
were no differences in body weight or BMI after the
treatment. Serum triglyceride levels at the end of the
study tended to decrease (P= 0.057). There were no
significant differences in total serum low-density
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had blood pressure measurements in the normal range
at the beginning of the study, and this was also the
case for the serum parameters (Table 2). After drink-
ing the beverage containing β-cryptoxanthin for
3 weeks, serum β-cryptoxanthin levels significantly
increased 4-fold. The results show that serum HMW-
adiponectin levels at the end of the study were signifi-
cantly higher compared with the initial period. Serum
total PAI-1 levels at the end of the study tended to be
lower (P= 0.052). The levels of other carotenoids, such
as lycopene, α-carotene, β-carotene, and zeaxanthin,
were not significantly different after the treatment.Discussion
This study investigated the potential effects of
β-cryptoxanthin supplementation on obesity. There were
no significant effects on body weight and BMI after the
3-week treatment. However, β-cryptoxanthin supple-
mentation improved the adipocytokine status, as indi-
cated by increased serum HMW-adiponectin levels and
decreased PAI-1 levels.
A previous study [7] reported that a Mediterranean
diet leads to increased serum adiponectin levels in meta-
bolic syndrome subjects. In a short-term study, Shimada
et al. [8] reported that supplementation of the diet of 17
elderly men with normal BMI values with Oolong tea
(1,000 ml/day) for 4 weeks increased the plasma adipo-
nectin levels, but without any decrease in body weight.
Sluijs et al. [9] reported that higher intake of dietaryTable 2 Comparison of FBG, serum lipid, adipocytokine,
and carotenoid levels before and after 3-weeks intake of
a β-cryptoxanthin beverage (n= 17)
Characteristics Before After Change* P-value
FBG (mg/dl) 101 ± 3 101 ± 2 1 0.749
Total-cholesterol (mg/dl) 216 ± 6 217 ± 6 1 0.827
LDL-cholesterol (mg/dl) 135 ± 6 136 ± 6 0 0.949
HDL-cholesterol (mg/dl) 64 ± 3 64 ± 3 0 0.803
Triglyceride (mg/dl) 116 ± 14 100 ± 12 −16 0.057
Leptin (mg/dl) 15.7 ± 1.8 15.5 ± 2.0 −0.2 0.853
HMW-Adiponectin (mg/ml) 9.8 ± 1.2 11.1 ± 1.1 1.3 0.009
Total PAI-1 (ng/ml) 32 ± 3 28 ± 3 −4 0.052
β-cryptoxanthin (mg/ml) 0.28 ± 0.04 1.15 ± 0.08 0.86 0.000
Lycopene (mg/ml) 0.18 ± 0.02 0.18 ± 0.01 0.00 0.741
α-carotene (mg/ml) 0.09 ± 0.02 0.09 ± 0.01 0.00 0.795
β-carotene (mg/ml) 0.37 ± 0.04 0.38 ± 0.03 0.00 0.793
Zeaxanthin (mg/ml) 0.07 ± 0.01 0.07 ± 0.01 0.00 0.901
Data show means ± S. E.
Abbreviations: FBG, fasting blood glucose; HMW, high molecular weight; PAI-1,
plasminogen activator inhibitor-1* Change implies subtraction of ‘before’ data
from ‘after’ data.carotenoid, particularly β-cryptoxanthin and lycopene,
was associated with a reduced prevalence of metabolic
syndrome in middle-aged elderly men. Daily β-
cryptoxanthin intakes in the Sluijs et al. [9] study were
1/37th of that found in the current study. However, the
dietary β-carotene and lycopene intake in the Sluijs et al.
[9] study was almost the same as that found in the
current study. Thus, daily consumption of milligram-
scale carotenoids, including, β-carotene, lycopene, and
β-cryptoxanthin, might alleviate metabolic syndrome.
Jones et al. [10] reported a correlation between serum
PAI-1 levels and carotenoid bioavailability in an inter-
vention study, where fish-oil esters of plant sterols were
added to the diets of moderately overweight and
hypercholesterolemic subjects over a period of 4 weeks.
Compared with supplementation with safflower oil
esters, supplementation with fish-oil esters of plant ster-
ols significantly elevated the serum levels of retinol and
β-carotenes and decreased serum PAI-1 levels. Thus, an
increased in serum carotenoid levels might result in a
decrease of serum PAI-1 levels. In this study, serum β-
cryptoxanthin levels increased, whereas PAI-1 levels
decreased.
In conclusion, increasing β-cryptoxanthin intake to ap-
proximately 4 mg per day for 3 weeks could have benefi-
cial effects on serum adipocytokine status, and
subsequently alleviate progression of metabolic syn-
drome. Further case–control study in larger scale may
be needed to prove sound relationships between β-
cryptoxanthin intake and the risk of development of
metabolic syndrome.
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